Adicet Bio. is a clinical-stage biotechnology company engaged in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product is an allogeneic CD20 targeted gamma delta T cell in phase 1 clinical studies for Non Hodgkin’s Lymphoma (NHL). The company has a pipeline of products including a GPC3 targeting gamma delta therapy for the treatment of Hepatocellular Carcinoma (HCC) partnered with Regeneron. Adicet is a VIPE (Venture Investment in Public Equity) and is listed on Nasdaq with the ticker ACET.